Chemotherapy | Number of patients, n (%) |
IV Carboplatin + IV Paclitaxel | 58 (16.6%) |
IV/IP Cisplatin + Paclitaxel | 52 (14.9%) |
Single-agent Carboplatin | 50 (14.4%) |
Single-agent Cisplatin | 28 (8%) |
Cisplatin + 5-fluorouracil | 19 (5.5%) |
Liposomal doxorubicin | 17 (4.9%) |
Carboplatin + liposomal doxorubicin | 15 (4.3%) |
Paclitaxel + bevacizumab | 15 (4.3%) |
EMA-CO | 13 (3.7%) |
Single-agent paclitaxel | 13 (3.7%) |
Gemcitabine | 9 (2.6%) |
Carboplatin + Gemcitabine | 6 (1.7%) |
Other, including trials | 53 (15.2%) |